Fish Oil Brain Claims Fail, L'Oréal Flags GLP-1 Shift

A landmark clinical trial just gutted fish oil's brain health story — and L'Oréal's CEO confirmed GLP-1 drugs are formally reshaping consumer spending. Two credibility moments supplement and health brands can't ignore. In this episode: A two-year clinical trial confirmed omega-3s from fish oil reached the brain but produced zero measurable improvement in memory or cognitive protection, directly threatening brain health claims across one of the supplement market's biggest categories. Italy's IAP censured Magic Magnesium Malate for implying its product could relieve restless legs and improve sleep, ruling that soft 'lifestyle language' carries the same evidential burden as explicit therapeutic claims. Cymbiotika is entering the ingestible beauty category off the back of 200 million liposomal sachets sold, using its bioavailability credentials as the primary trust mechanism in a fast-growing segment. L'Oréal's CEO publicly described GLP-1 drug adoption as 'a very important phenomenon' reshaping beauty and skincare purchasing, formally validating the GLP-1 consumer as a high-priority segment for supplement and nutraceutical brands. The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day. Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us. Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily